Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
Erasca Inc ERAS
$14.25
▼ -1.86%
($-0.27)
Open
$14.62
Prev Close
$14.52
Day Range
$14.23 – $14.89
52W Range
$1.78 – $24.28
Market Cap
$4.98B
Beta
0.70
EPS (TTM)
$-0.95
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-07-15 |
| Shares Out. | 342,240,000 |
| Website | erasca.com/ ↗ |
| Phone | 18584656511 |
| Employees | 103 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$44.1M |
| Free Cash Flow | -$98.1M |
| Total Assets | $435.1M |
| Total Liabilities | $73.2M |
| Equity | $361.9M |
About Erasca Inc
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
Erasca Inc is a publicly traded company under the ticker symbol ERAS on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
17 analysts (2026-09-01)